901m$ Q2'20 sales for Darzalex $GMAB $JNJ, from 774m$ in Q2'19 (+16.4%), and 937m$ in Q1'20 (-3.8%). Apparently a potential faster adoption of the SC formulation didn't manage to offset completely some delays in IV infusions.